Ireland
--:--IST
Latest
Airmid Éireann 1.4 Puts Irish Pharma Data in Global Context Northern Ireland Phone Switch-Off: Check Medical Devices Irish Medtech Calls for MDR and IVDR Reform at Galway Event Clonmel Healthcare Launches Mabelle Menocare Supplements HealthSpan Partners to Acquire Irish GP Group Centric Health Outpatient Waiting List Reaches 692,524, Up 10.5% in a Year Airmid Éireann 1.4 Puts Irish Pharma Data in Global Context Northern Ireland Phone Switch-Off: Check Medical Devices Irish Medtech Calls for MDR and IVDR Reform at Galway Event Clonmel Healthcare Launches Mabelle Menocare Supplements HealthSpan Partners to Acquire Irish GP Group Centric Health Outpatient Waiting List Reaches 692,524, Up 10.5% in a Year
Clinical Trials in France / NCT06848816
Active, not recruiting Observational

Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis (AGPN): Effect on the Risk of Recurrence

NCT06848816 · tracked via the Priya Life Science France tracker
Sponsor
Central Hospital, Nancy, France
Phase
Observational
Started
2020-01-01
Last updated
2025-02-27

Condition(s) studied

Pyelonephritis AcuteKidney Transplantation Recipients

Study summary

The aim of this study is to evaluate the impact of the duration of antibiotic therapy on the risk of recurrence in kidney graft pyelonephritis. The secondary objectives are to identify the factors associated with the duration of antibiotic therapy in acute kidney graft pyelonephritis, identify the factors associated with recurrence of acute kidney graft pyelonephritis within 3 months, evaluate the impact of the duration of antibiotic therapy on antibiotic-related complications and assess the impact of the duration of antibiotic therapy on the progression of renal function after acute kidney graft pyelonephritis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients * Kidney transplant recipients with a functional graft. * Hospitalization with acute pyelonephritis (APN) defined by fever OR chills (noted in the clinical records) AND bacteriuria AND exclusion of another obvious cause of fever. (For rehospitalizations, also include cases where antibiotic therapy was initiated based on suspicion, even in the absence of documented infection.) Exclusion Criteria: * Age \< 18 years. * Vacationing patient or lost to follow-up with follow-up \< 3 months.

Primary outcome measure(s)

  • Relaspe AGPN — 3 month
    Rehospitalization for acute kidney graft pyelonephritis (AGPN) within three months after completion of treatment

Trial sites (1)

FacilityCityRegionStatus
CHU de Nancy Nancy France

More Central Hospital, Nancy, France trials in France

STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2 Active, not recruiting
Optimization of the Acquisition Sequence to Improve the Quality and Comfort of Magnetic Resonance Imaging Exam Recruiting
Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke Recruiting
Acute Heart Failure - COngestion Discharge Evaluation Recruiting
Cerebral Near Infrared Spectroscopy in Out-of-Hospital Cardiac Arrest and Neurological Prognosis Starting soon

Other trials for the same condition

3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children Recruiting
Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06848816 on ClinicalTrials.gov ↗ ← All trials in France